Marshall Wace
GTHX

Marshall Wace’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Marshall Wace’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-360,293
Closed -$1.1M – 2890
2023
Q4 		$1.1M Sell
360,293
-156,435
-30% -$294K ﹤0.01% 1439
2023
Q3 		$744K Buy
516,728
+461,128
+829% +$892K ﹤0.01% 1591
2023
Q2 		$138K Sell
55,600
-707,776
-93% -$1.93M ﹤0.01% 2293
2023
Q1 		$2.05M Sell
763,376
-231,612
-23% -$1.11M ﹤0.01% 1449
2022
Q4 		$5.4M Buy
994,988
+362,810
+57% +$3.04M 0.01% 1141
2022
Q3 		$7.89M Buy
632,178
+155,356
+33% +$1.77M 0.02% 1063
2022
Q2 		$2.35M Buy
476,822
+377,801
+382% +$2.09M ﹤0.01% 1879
2022
Q1 		$753K Buy
+99,021
New +$939K ﹤0.01% 2579
2020
Q1 		– Sell
-17,944
Closed -$474K – 2146
2019
Q4 		$474K Buy
+17,944
New +$420K ﹤0.01% 1192
2019
Q3 		– Sell
-189,486
Closed -$5.81M – 1975
2019
Q2 		$5.81M Buy
189,486
+104,562
+123% +$2.2M 0.05% 432
2019
Q1 		$1.41M Sell
84,924
-301,586
-78% -$5.72M 0.01% 837
2018
Q4 		$7.4M Buy
386,510
+342,990
+788% +$12.8M 0.08% 330
2018
Q3 		$2.28M Buy
+43,520
New +$2.37M 0.02% 651

Other funds holding GTHX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace's GTHX Position: Q1 2024 in Review

Marshall Wace sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2024, closing a stake of 360,293 shares — an estimated $1.1M sold.

Marshall Wace first reported a position in GTHX in Q3 2018 and held it in 13 quarters. The position peaked at $7.89M in Q3 2022. 86 funds tracked by Wall St. Rank hold GTHX as of Q1 2024.

  • Marshall Wace reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Marshall Wace sold 360,293 G1 Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.1M.
  • Marshall Wace first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2018 and held it in 13 quarters.
  • Marshall Wace's G1 Therapeutics, Inc. Common Stock position peaked at $7.89M in Q3 2022.
  • 86 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Marshall Wace's 13F filing for Q1 2024, filed 15 May 2024.